Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report

BACKGROUND: The treatment landscape of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation has significantly changed in the past decade. However, EGFR exon 20 insertion (20ins), which accounts for at least 9% of all EGFR mutated cases, has been generally ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Keyi, Yang, Shuo, Chen, Bin, Yu, Jia, Wu, Yan, Li, Wei, Zhou, Fei, Wu, Fengying, Feng, Gaohua, Ren, Shengxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011291/
https://www.ncbi.nlm.nih.gov/pubmed/35433998
http://dx.doi.org/10.21037/atm-22-1167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011291/
https://www.ncbi.nlm.nih.gov/pubmed/35433998
http://dx.doi.org/10.21037/atm-22-1167

Ejemplares similares